Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

Journal of Immunotherapy

Volumn 36, Issue 7, 2013, Pages 382-389

  Le, Dung T ^a,b   Lutz, Eric ^a   Uram, Jennifer N ^a   Sugar, Elizabeth A ^a,c   Onners, Beth ^a   Solt, Sara ^a   Zheng, Lei ^a   Diaz Jr , Luis A ^b   Donehower, Ross C ^a   Jaffee, Elizabeth M ^a   Laheru, Daniel A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CTLA 4; GVAX; Ipilimumab; Pancreatic cancer; Vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRY EYE; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENETIC TRANSFECTION; GUILLAIN BARRE SYNDROME; HUMAN; HYPOPHYSITIS; MALE; MUSCLE CRAMP; NAUSEA; NEPHRITIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; GPI-LINKED PROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; TRANSFECTION;

EID: 84883207410     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31829fb7a2     Document Type: Article

References (21)

1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
2. De Jesus-Acosta A, Oliver GR, Blackford A, et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69: 415-424.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: 411-422.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364: 2517-2526.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-2454.
6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366: 2455-2465.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
8. Jaffee EM, Hruban RH, Biedrzycki B. Novel allogeneic granulocyte- macrophage lony stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety an immune activation. J Clin Oncol. 2001;19: 145-156. (Pubitemid 32063491)
9. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colonystimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14: 1455-1463. (Pubitemid 351413929)
10. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic nulocyte macrophage colony stimulating factorsecreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253: 328-335.
11. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelinspecific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200: 297-306. (Pubitemid 39031249)
12. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33: 828-833.
13. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21: 1712-1717.
14. Van Elsa AHA, Allison JP. Combination immunotherapy of B16 Melanoma using anti-cytotoxic T lymphocyte-associated antigen (CTLA-4) and granulocyte/macrophage colonystimulating factor (GM-CSF) producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190: 355-366. (Pubitemid 29374833)
15. Hurwitz AA, Leach DR, Allison JP. CTLA-4 blockade synergizes with mor derived granulocyte-macrophage colonystimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA. 1998;95: 10067-10071. (Pubitemid 28415295)
16. Hurwitz AA, Kwon ED, Foster BA, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000; 60: 2444-2448. (Pubitemid 30262435)
17. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15: 7412-7420.
18. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony- stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13: 509-517.
19. Murata S, Ladle BH, Kim PS, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol. 2006;176: 974-983. (Pubitemid 43099696)
20. Li B, VanRoey M, Wang C, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15: 1623-1634.
21. Li B, Lin J, Vanroey M, et al. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol. 2007;125: 76-87. (Pubitemid 47374542)